Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00949975 · ClinicalTrials.gov registry record · Phase 2

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

A Phase 2 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
838
Enrollment target

NCT00949975: Completed Phase 2 study, sponsored by AstraZeneca.

NCT00949975 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 838 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (530% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00949975, a Phase 2 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
838 participants
Enrollment target

Study Summary

The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.

Primary Outcome

Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic

Interventions

  • DRUG AZD9668
  • DRUG AZD9668 Placebo

Trial Details

FieldValue
Enrollment Target 838 participants
Start Date 2009-07
Est. Completion 2010-08
Phase Phase 2
AstraZeneca

1,285 total trials

What the finished NCT00949975 record still lists

NCT00949975 is an interventional study that assigns participants to a tested intervention. The registered 838 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (530% higher).

The record links to 0 conditions, and to 2 interventions - of which AZD9668 is the first listed.

NCT00949975 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00949975 about?

NCT00949975 is a clinical study titled "A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium". The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.

What is the current status of trial NCT00949975?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 838 participants. The study started on 2009-07. Estimated completion is 2010-08.

What interventions are being tested in trial NCT00949975?

The interventions under investigation include: AZD9668 (DRUG), AZD9668 Placebo (DRUG).

Who is sponsoring clinical trial NCT00949975?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00949975's enrollment target sits among peer trials

838 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422550 · 837 participants

    Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment

  • NCT04831580 · 840 participants · NA

    A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

  • NCT04976881 · 840 participants · NA

    Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes

  • NCT04985903 · 840 participants · NA

    Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00949975, the US trial registry maintained by the National Library of Medicine. NCT00949975 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.